1102 related articles for article (PubMed ID: 18003960)
1. Cetuximab for the treatment of colorectal cancer.
Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
[TBL] [Abstract][Full Text] [Related]
2. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
8. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
9. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
[TBL] [Abstract][Full Text] [Related]
12. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
16. FDA drug approval summary: panitumumab (Vectibix).
Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
[TBL] [Abstract][Full Text] [Related]
18. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
19. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
Pantelic A; Markovic M; Pavlovic M; Jancic S
J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]